Vanda Pharmaceuticals Inc. (VNDA) Holdings Lifted by State Street Corp

State Street Corp grew its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 2.9% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,618,485 shares of the biopharmaceutical company’s stock after acquiring an additional 46,299 shares during the period. State Street Corp owned about 3.61% of Vanda Pharmaceuticals worth $26,380,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in VNDA. Stonepine Capital Management LLC grew its holdings in Vanda Pharmaceuticals by 1,482.2% during the 2nd quarter. Stonepine Capital Management LLC now owns 685,086 shares of the biopharmaceutical company’s stock worth $11,167,000 after acquiring an additional 641,786 shares in the last quarter. FMR LLC grew its holdings in Vanda Pharmaceuticals by 60.7% during the 1st quarter. FMR LLC now owns 1,601,171 shares of the biopharmaceutical company’s stock worth $22,416,000 after acquiring an additional 604,900 shares in the last quarter. Vanguard Group Inc. grew its holdings in Vanda Pharmaceuticals by 26.4% during the 1st quarter. Vanguard Group Inc. now owns 2,494,347 shares of the biopharmaceutical company’s stock worth $34,920,000 after acquiring an additional 521,669 shares in the last quarter. AJO LP grew its holdings in Vanda Pharmaceuticals by 94.2% during the 2nd quarter. AJO LP now owns 541,927 shares of the biopharmaceutical company’s stock worth $8,833,000 after acquiring an additional 262,833 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Vanda Pharmaceuticals by 16.9% during the 2nd quarter. Renaissance Technologies LLC now owns 1,097,950 shares of the biopharmaceutical company’s stock worth $17,897,000 after acquiring an additional 158,700 shares in the last quarter. 87.28% of the stock is owned by institutional investors.

WARNING: This report was first posted by Markets Daily and is the property of of Markets Daily. If you are reading this report on another website, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this report can be viewed at https://www.themarketsdaily.com/2017/11/14/vanda-pharmaceuticals-inc-vnda-holdings-lifted-by-state-street-corp.html.

Vanda Pharmaceuticals Inc. (NASDAQ VNDA) opened at $12.95 on Tuesday. Vanda Pharmaceuticals Inc. has a 52-week low of $11.90 and a 52-week high of $18.99.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10). The firm had revenue of $41.30 million for the quarter, compared to the consensus estimate of $43.90 million. Vanda Pharmaceuticals had a negative net margin of 9.01% and a negative return on equity of 10.99%. Vanda Pharmaceuticals’s quarterly revenue was up 7.3% compared to the same quarter last year. During the same period last year, the firm posted ($0.01) EPS. research analysts anticipate that Vanda Pharmaceuticals Inc. will post -0.39 earnings per share for the current fiscal year.

VNDA has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Wednesday, October 18th. Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, September 14th. Piper Jaffray Companies set a $23.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. HC Wainwright set a $18.00 price target on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Finally, Jefferies Group LLC restated a “buy” rating and issued a $21.00 price target on shares of Vanda Pharmaceuticals in a research report on Tuesday, August 29th. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. Vanda Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $21.50.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply